Huge Red Flag with Lenacapavir

PrEP consumers might be getting a little IRIS with their shot - BEWARE

Remember all the headlines a few months back about the breakthrough in “HIV” prevention, the twice yearly injection that was authorized for use for PrEP in 2022 following the much lauded “no seroconversion” trial? (Except, oops, the next trial did show seroconversion.)

What if I told you that the risk of immune reconstitution syndrome (IRIS) is so common on lenacapavir that the company selling it under the brand name Sunlenca now has a warning about IRIS at the very top of their page. Check it out:

A NOVEL, FIRST-IN-CLASS CAPSID INHIBITOR1

• Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported in patients treated with combination antiretroviral (ARV) therapy.

Translation: Immune reconstitution syndrome is the phenomenon of developing AIDS, in the form of opportunistic infections, while taking ARVs, in part because of the ARVs. No wonder we have no idea of how to count AIDS deaths because clearly, provably, patients have died from these drugs. But here’s the most disturbing part of the whole thing: Lenacapavir is being pushed for PrEP, despite the fact that—admitted by the drug’s own developer—it can actually cause immune deficiency by itself. They’re basically admitting that their “anti-HIV” drug might cause AIDS defining conditions in “HIV” negative individuals, who are presumably taking it to AVOID AIDS. This is completely insane.

What in the hell is really behind the push for PrEP? I’m growing more suspicious by the day. Let me know what you think in the comments.